Skip to content

Medical Mutual

Does Medical Mutual cover Wegovy?

It depends on your benefits. Medical Mutual covers Wegovy for weight loss only when your plan includes that benefit and the policy requirements are met.

Policy document

  • Employer: Depends on your plan's benefit. See the qualification pathways below.

Earliest policy review June 10, 2026. How we verify · Check your exact plan

Full requirements: Wegovy for Weight Loss (1 plan type)

Applies to Employer plans.

Depends on your plan's benefit

Prior Authorization is only available for members with plan benefit coverage of weight loss drugs. Medications for the treatment of weight loss are specifically excluded as a covered benefit for many plans.

Qualification pathways

You can qualify through any one of these.

Adult Initial Therapy (age ≥ 18)

All of:

  • Patient is ≥ 18 years of age
  • Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months
  • Wegovy will be used concomitantly with a behavioral modification program and a reduced-calorie diet
  • Prescriber does not specialize primarily in: anesthesiology, dentistry, emergency medicine, nuclear medicine, ophthalmology, pathology, or radiology

Plus any one of:

  • At baseline, patient had a BMI ≥ 32 kg/m2
  • At baseline, patient had a BMI ≥ 27 kg/m2 AND at least TWO of the following weight-related comorbidities: hypertension, type 2 diabetes, dyslipidemia, OSA, CVD, knee osteoarthritis, asthma, COPD, NASH/NAFLD, PCOS, or CAD

Adult Continuation Therapy (age ≥ 18)

All of:

  • Patient is ≥ 18 years of age
  • Patient has lost ≥ 5% of baseline body weight
  • Wegovy will be used concomitantly with a behavioral modification program and a reduced-calorie diet
  • Prescriber does not specialize primarily in: anesthesiology, dentistry, emergency medicine, nuclear medicine, ophthalmology, pathology, or radiology
  • Patient has completed at least 7 months of initial therapy OR is within initial approval period

Plus any one of:

  • At baseline, patient had a BMI ≥ 32 kg/m2
  • At baseline, patient had a BMI ≥ 27 kg/m2 AND at least TWO weight-related comorbidities

Pediatric Initial Therapy (age 12 to <18)

All of:

  • Patient is ≥ 12 years of age and < 18 years of age
  • Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months
  • At baseline, patient had a BMI ≥ 95th percentile for age and sex
  • Wegovy (injectable only) will be used concomitantly with behavioral modification and a reduced-calorie diet
  • Prescriber does not specialize primarily in: anesthesiology, dentistry, emergency medicine, nuclear medicine, ophthalmology, pathology, or radiology

Pediatric Continuation Therapy (age 12 to <18)

All of:

  • Patient is ≥ 12 years of age and < 18 years of age
  • At baseline, patient had a BMI ≥ 95th percentile for age and sex
  • Patient has had a reduction in BMI of ≥ 1% from baseline
  • Wegovy (injectable only) will be used concomitantly with behavioral modification and a reduced-calorie diet
  • Prescriber does not specialize primarily in: anesthesiology, dentistry, emergency medicine, nuclear medicine, ophthalmology, pathology, or radiology
  • Patient has completed at least 7 months of initial therapy OR is within initial approval period

Plus any one of:

  • Patient is able to tolerate a Wegovy maintenance dose of 1.7 mg or 2.4 mg once weekly (approve for 1 year)
  • Patient has received < 12 consecutive months of Wegovy AND prescriber confirms patient is continuing to titrate to target dose (approve up to 5 months)

Documentation to bring

  • Documentation of baseline BMI (≥ 32 kg/m2, OR ≥ 27 kg/m2 with at least two qualifying comorbidities) prior to any GLP-1 or GLP-1/GIP agonist use
  • Documentation of at least 3-month trial of behavioral modification and dietary restriction
  • For BMI ≥ 27 pathway: documentation of at least two qualifying weight-related comorbidities
  • For pediatric patients: documentation of baseline BMI ≥ 95th percentile for age and sex
  • For continuation: documentation of ≥ 5% baseline body weight loss (adults) or ≥ 1% BMI reduction from baseline (pediatric)
  • For continuation: prescriber attestation of ability to tolerate maintenance dose or confirmation of ongoing dose titration
  • Prescriber specialty credentials (to confirm not in excluded specialty)

Approval and renewal

  • Initial approval: 7 months
  • Renewal: every 12 months
  • Renewal: At least 1% reduction in BMI.
  • Renewal: Adult: must have lost ≥ 5% of baseline body weight. Pediatric (12-<18): must have had a reduction in BMI of ≥ 1% from baseline. Patient must be able to tolerate injectable maintenance dose of 1.7 mg or 2.4 mg once weekly OR oral maintenance dose of 25 mg once daily for 1-year approval; alternatively, if still titrating and <12 consecutive months received, approve for up to 5 months. Baseline BMI eligibility is re-verified at continuation.
  • Renewal: Staying on a maintenance dose of at least 1.7 mg.

Not covered when

  • Concomitant use with other FDA-approved weight loss medications (e.g., phentermine, benzphetamine, diethylpropion, phendimetrazine, Contrave, Qsymia, orlistat)
  • Concomitant use with other GLP-1 agonists or GLP-1/GIP agonists
  • Prescriber who specializes primarily in: anesthesiology, dentistry, emergency medicine, nuclear medicine, ophthalmology, pathology, or radiology

Policy note: Annual Review Date listed as 07/17/2025; Last Revised Date 01/15/2026. Wegovy is available as oral or injectable for adult weight loss; injectable only for pediatric weight loss. Baseline BMI refers to baseline prior to any GLP-1 or GLP-1/GIP agonist use. Coverage is generally not available unless the member's plan includes weight loss drug benefits. Initial approval for adults is 7 months; continuation approval is up to 1 year if maintenance dose tolerated, or up to 5 months if still titrating (with sufficient duration to reach 12 consecutive months total).

verified June 10, 2026 · source: Weight Loss Glucagon Like Peptide1 GLP-1 Agonists · View policy document (PDF)

Open on its own page →

Full requirements: Wegovy for Heart Disease Risk Reduction (1 plan type)

Applies to Employer plans.

Depends on your plan's benefit

Prior Authorization is only available for members with plan benefit coverage of weight loss drugs. Medications for the treatment of weight loss are specifically excluded as a covered benefit for many plans.

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction in Established CVD with Obesity/Overweight

All of:

  • Patient is ≥ 18 years of age
  • Patient has a BMI ≥ 27 kg/m2
  • According to the prescriber, the medication will be used in combination with optimized pharmacotherapy for established cardiovascular disease
  • Medication will be used concomitantly with a behavioral modification program and a reduced-calorie diet

Plus any one of:

  • Patient has had a prior myocardial infarction
  • Patient has had a prior stroke (not including TIA)
  • Patient has a history of symptomatic peripheral arterial disease evidenced by: intermittent claudication with ankle-brachial index < 0.85, OR peripheral arterial revascularization procedure, OR amputation due to atherosclerotic disease

Documentation to bring

  • Documentation of BMI ≥ 27 kg/m2
  • Documentation of qualifying cardiovascular event: prior MI, prior stroke (not TIA), or symptomatic PAD (with ankle-brachial index < 0.85, revascularization, or amputation due to atherosclerotic disease)
  • Prescriber attestation that medication will be used in combination with optimized pharmacotherapy for established cardiovascular disease

Approval and renewal

  • Initial approval: 6 months

Not covered when

  • Transient ischemic attack (TIA) does not qualify as a prior stroke
  • Concomitant use with other FDA-approved weight loss medications
  • Concomitant use with other GLP-1 agonists or GLP-1/GIP agonists

Policy note: Approval is for 6 months initial duration. No explicit continuation criteria listed for CV risk reduction indication. Wegovy oral or injectable forms are both applicable. The policy does not explicitly state that diabetes is excluded for this indication — no excludes diabetes flag applied.

verified June 10, 2026 · source: Weight Loss Glucagon Like Peptide1 GLP-1 Agonists · View policy document (PDF)

Open on its own page →

If weight loss isn't covered on your plan

Medical Mutual has separate Wegovy policies that don't depend on that benefit:

Questions people ask
Does Medical Mutual cover Wegovy?
It depends on your benefits. Medical Mutual covers Wegovy for weight loss only when your plan includes that benefit and the policy requirements are met.
How long does a Wegovy approval last with Medical Mutual?
Weight Loss — Applies to Employer plans. Initial approval: 7 months. Renewal: every 12 months. Heart Disease Risk Reduction — Applies to Employer plans. Initial approval: 6 months.
What does Medical Mutual require to renew Wegovy?
Weight Loss — Applies to Employer plans. At least 1% reduction in BMI. Adult: must have lost ≥ 5% of baseline body weight. Pediatric (12-<18): must have had a reduction in BMI of ≥ 1% from baseline. Patient must be able to tolerate injectable maintenance dose of 1.7 mg or 2.4 mg once weekly OR oral maintenance dose of 25 mg once daily for 1-year approval; alternatively, if still titrating and <12 consecutive months received, approve for up to 5 months. Baseline BMI eligibility is re-verified at continuation. Staying on a maintenance dose of at least 1.7 mg.
How current is this information?
The oldest review date among the policies on this page is June 10, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under Medical Mutual: Ozempic, Zepbound

Wegovy under other plans: Elevance Health, Ohio Medicaid, Alabama Medicaid, California Medicaid, Clover Health, Colorado Medicaid, Connecticut Medicaid, Delaware Medicaid

All insurance plans · All medications

Summary of Medical Mutual's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.